BR112022025551A2 - Tratamento de disfunção atrial - Google Patents

Tratamento de disfunção atrial

Info

Publication number
BR112022025551A2
BR112022025551A2 BR112022025551A BR112022025551A BR112022025551A2 BR 112022025551 A2 BR112022025551 A2 BR 112022025551A2 BR 112022025551 A BR112022025551 A BR 112022025551A BR 112022025551 A BR112022025551 A BR 112022025551A BR 112022025551 A2 BR112022025551 A2 BR 112022025551A2
Authority
BR
Brazil
Prior art keywords
dysfunction treatment
atrial dysfunction
atrial
treatment
patient
Prior art date
Application number
BR112022025551A
Other languages
English (en)
Portuguese (pt)
Inventor
Tamby Jean-Francois
M Edelberg Jay
Howard Takeo Kurio Gregory
Lyle Kelly Cynthia
Yang Chun
Patrick Henze Marcus
L Del Rio Carlos
Lee Anderson Robert
P Sumandea Marius
Ganju Jitendra
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of BR112022025551A2 publication Critical patent/BR112022025551A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112022025551A 2020-06-15 2021-06-14 Tratamento de disfunção atrial BR112022025551A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063039438P 2020-06-15 2020-06-15
US202063042512P 2020-06-22 2020-06-22
PCT/US2021/037230 WO2021257456A1 (en) 2020-06-15 2021-06-14 Treatment of atrial dysfunction

Publications (1)

Publication Number Publication Date
BR112022025551A2 true BR112022025551A2 (pt) 2023-03-07

Family

ID=76845320

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025551A BR112022025551A2 (pt) 2020-06-15 2021-06-14 Tratamento de disfunção atrial

Country Status (13)

Country Link
US (1) US20230233545A1 (cg-RX-API-DMAC7.html)
EP (1) EP4164644A1 (cg-RX-API-DMAC7.html)
JP (2) JP7832128B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230024977A (cg-RX-API-DMAC7.html)
CN (1) CN116056703A (cg-RX-API-DMAC7.html)
AU (1) AU2021293817A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025551A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180943A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003548A1 (cg-RX-API-DMAC7.html)
IL (1) IL298885A (cg-RX-API-DMAC7.html)
MX (1) MX2022015488A (cg-RX-API-DMAC7.html)
TW (1) TW202214241A (cg-RX-API-DMAC7.html)
WO (1) WO2021257456A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759640B2 (en) * 2022-01-07 2023-09-19 Xyra, Llc Methods for reducing the risk of strokes by pharmacotherapy to reduce the number and duration of atrial fibrillations
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
CN117815534A (zh) * 2023-12-12 2024-04-05 苏州晟智医疗科技有限公司 反搏辅助装置、计算设备、存储介质及反搏系统
CN119157623A (zh) * 2023-12-12 2024-12-20 成都迈格因科技有限公司 一种经导管心脏射频消融的蒸汽爆破安全预警和控制系统
CN118304374A (zh) * 2024-04-01 2024-07-09 山东省中医药研究院附属医院 一种组合物在制备治疗心动过速和/或瓣膜反流药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201705928XA (en) * 2015-01-22 2017-08-30 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
US10758525B2 (en) * 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
CA3060702A1 (en) * 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
JP2020526483A (ja) * 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
SG11202112723PA (en) * 2019-05-19 2021-12-30 Myokardia Inc Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Also Published As

Publication number Publication date
AU2021293817A1 (en) 2023-01-19
JP2026048841A (ja) 2026-03-17
WO2021257456A1 (en) 2021-12-23
JP7832128B2 (ja) 2026-03-17
TW202214241A (zh) 2022-04-16
EP4164644A1 (en) 2023-04-19
CN116056703A (zh) 2023-05-02
KR20230024977A (ko) 2023-02-21
US20230233545A1 (en) 2023-07-27
CL2022003548A1 (es) 2023-06-09
MX2022015488A (es) 2023-03-21
IL298885A (en) 2023-02-01
CA3180943A1 (en) 2021-12-23
JP2023529502A (ja) 2023-07-10

Similar Documents

Publication Publication Date Title
CO2020008988A2 (es) Oligonucleótidos antisentido para alfa-sinucleína y usos de los mismos
CL2022003548A1 (es) Tratamiento de la disfunción auricular
MX2021010329A (es) Composicion farmaceutica que comprende empagliflozina y sus usos.
PE20180260A1 (es) Metodos y kits para tratar la depresion
PH12020551427A1 (en) Epinephrine spray formulations
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
AR100560A1 (es) Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido
MX2018011348A (es) Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades.
CL2017000864A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
CL2021003045A1 (es) Tratamiento de la disfunción sistólica
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
BR112016019432A8 (pt) composição terapêutica, kit e seus usos na terapia gênica contra degeneração da retina
BR112021021676A2 (pt) Uso de preparação de exossomo de células-tronco mesenquimais para a preparação de composição para o tratamento da doença periodontal
BR112017012581A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras
MX2015012176A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
CO2017006032A2 (es) Métodos para tratar la calcificación de tejidos
BR112022015015A2 (pt) Usos terapêuticos de tirzepatida
MX2017016347A (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.
CL2019002313A1 (es) Combinación de cotinina y antioxidante para la resistencia al tratamiento de la depresión y corrección del déficit funcional de los astrocitos inducido por la depresión y otras afecciones neuropatológicas.
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.